FDA Delay Will Not Push Rocket Pharma Off Its Trajectory
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.